-- Pre-clinical collaboration with Mayo Clinic on track --
Oxford, UK – 1 July 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update on Glaucoma-GT, a novel gene-based therapy for the treatment of uncontrolled chronic glaucoma. In collaboration with Mayo Clinic, Rochester (USA), Oxford BioMedica is conducting pre-clinical studies to establish the feasibility of treating glaucoma using its proprietary LentiVector® gene delivery technology expressing a COX-2 gene and a PGF-2α receptor gene in order to reduce intraocular pressure.
Over the past 18 months, Oxford BioMedica has successfully completed initial pre-clinical studies to demonstrate that the LentiVector® platform is both well-tolerated at high vector dose and transduces suitable target cells following transcorneal injection into the front of the eye. In January 2013, the Company decided to evaluate a more translational glaucoma model in order to maximise proof of concept data. Results from this new pre-clinical model have shown:
• Successful transduction of target cells following transcorneal delivery to the front of the eye
• Favourable safety profile at highest vector dose
• Long-term gene expression out to furthest time point studied (five months)
Oxford BioMedica now plans to initiate its first pre-clinical efficacy study which will evaluate, amongst other measures, the lowering of intraocular pressure. The Company continues to move Glaucoma-GT towards future clinical development, furthering its growing ophthalmology portfolio.
John Dawson, Chief Executive Officer of Oxford BioMedica, said: “Pre-clinical and clinical data in a variety of indications suggest that a single application of our LentiVector®platform products can provide sustained or permanent therapeutic activity. There remains a large unmet medical need in a significant proportion of the glaucoma patient population and, by providing long-term control of intraocular pressure, this approach could minimise the risk of disease progression.”
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips
Tel: +44 (0)20 3709 5700